FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016097788> ?p ?o ?g. }

• W3016097788 endingPage "e000377" @default.
• W3016097788 startingPage "e000377" @default.
• W3016097788 abstract "Objective To evaluate 12-month outcomes in treatment-naïve patients with neovascular (wet) age-related macular degeneration (AMD) stratified by intravitreal aflibercept (IVT-AFL) regimen. Methods and analysis Patients included in the 12-month interim analysis of Real life of intravitreal Aflibercept In FraNce: oBservatiOnal Study in Wet AMD (RAINBOW), a 4-year, ongoing observational study conducted in France, were stratified by IVT-AFL dosing regimen. Safety (n=593) and effectiveness (n=428) data were analysed. Regimens included a regular cohort (three initial monthly IVT-AFL injections and ≥6 injections) and irregular cohorts (<6 injections) with and without three initial monthly injections. The main outcome measure was mean gain in best-corrected visual acuity (BCVA) at 12 months. Results Mean number of IVT-AFL injections was 6.0 (all patients, n=513), 7.2 (regular cohort, n=102), 6.1 (irregular cohort with three initial monthly injections, n=266) and 5.2 (irregular cohort without three initial monthly injections, n=60). Overall mean gain in BCVA at 12 months was 5 letters; +7.1 letters (regular cohort) and +5.6 letters (irregular cohort with three initial monthly injections), both p<0.001 versus baseline, and –1.1 letters (irregular cohort without three initial monthly injections), p=0.669. Improvements in BCVA were also significantly greater in the regular cohort (p<0.001) and irregular cohort with three initial monthly injections (p=0.003) compared with the irregular cohort without three initial monthly injections. Ocular and non-ocular adverse events were reported in 14.7% and 17.4% of all patients, respectively. Conclusion Treatment-naïve patients with neovascular AMD receiving three initial monthly injections followed by regular or irregular injections over 12 months experienced better visual acuity outcomes than those receiving irregular treatment without three initial monthly injections. Trial registration number NCT02279537 ." @default.
• W3016097788 created "2020-04-17" @default.
• W3016097788 creator A5002766435 @default.
• W3016097788 creator A5031143082 @default.
• W3016097788 creator A5048002297 @default.
• W3016097788 creator A5052978557 @default.
• W3016097788 creator A5053183041 @default.
• W3016097788 creator A5060131326 @default.
• W3016097788 creator A5069476269 @default.
• W3016097788 date "2020-04-01" @default.
• W3016097788 modified "2023-09-25" @default.
• W3016097788 title "Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study" @default.
• W3016097788 cites W1044276697 @default.
• W3016097788 cites W1576012659 @default.
• W3016097788 cites W1968189763 @default.
• W3016097788 cites W1980502776 @default.
• W3016097788 cites W1996171994 @default.
• W3016097788 cites W1997480136 @default.
• W3016097788 cites W2003324689 @default.
• W3016097788 cites W2004117352 @default.
• W3016097788 cites W2075984382 @default.
• W3016097788 cites W2085712747 @default.
• W3016097788 cites W2093044616 @default.
• W3016097788 cites W2124415048 @default.
• W3016097788 cites W2134161293 @default.
• W3016097788 cites W2146673937 @default.
• W3016097788 cites W2157204458 @default.
• W3016097788 cites W2161400914 @default.
• W3016097788 cites W2184100967 @default.
• W3016097788 cites W2265083335 @default.
• W3016097788 cites W2533538659 @default.
• W3016097788 cites W2583647603 @default.
• W3016097788 cites W2610506892 @default.
• W3016097788 cites W2616502721 @default.
• W3016097788 cites W2768622840 @default.
• W3016097788 cites W2827990227 @default.
• W3016097788 cites W2939954100 @default.
• W3016097788 cites W343466161 @default.
• W3016097788 cites W4250031098 @default.
• W3016097788 cites W4361738959 @default.
• W3016097788 doi "https://doi.org/10.1136/bmjophth-2019-000377" @default.
• W3016097788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7254134" @default.
• W3016097788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32518833" @default.
• W3016097788 hasPublicationYear "2020" @default.
• W3016097788 type Work @default.
• W3016097788 sameAs 3016097788 @default.
• W3016097788 citedByCount "8" @default.
• W3016097788 countsByYear W30160977882020 @default.
• W3016097788 countsByYear W30160977882021 @default.
• W3016097788 countsByYear W30160977882022 @default.
• W3016097788 countsByYear W30160977882023 @default.
• W3016097788 crossrefType "journal-article" @default.
• W3016097788 hasAuthorship W3016097788A5002766435 @default.
• W3016097788 hasAuthorship W3016097788A5031143082 @default.
• W3016097788 hasAuthorship W3016097788A5048002297 @default.
• W3016097788 hasAuthorship W3016097788A5052978557 @default.
• W3016097788 hasAuthorship W3016097788A5053183041 @default.
• W3016097788 hasAuthorship W3016097788A5060131326 @default.
• W3016097788 hasAuthorship W3016097788A5069476269 @default.
• W3016097788 hasBestOaLocation W30160977881 @default.
• W3016097788 hasConcept C118487528 @default.
• W3016097788 hasConcept C126322002 @default.
• W3016097788 hasConcept C141071460 @default.
• W3016097788 hasConcept C167135981 @default.
• W3016097788 hasConcept C197934379 @default.
• W3016097788 hasConcept C201903717 @default.
• W3016097788 hasConcept C23131810 @default.
• W3016097788 hasConcept C2776403814 @default.
• W3016097788 hasConcept C2776694085 @default.
• W3016097788 hasConcept C2777288759 @default.
• W3016097788 hasConcept C2777802072 @default.
• W3016097788 hasConcept C2778257484 @default.
• W3016097788 hasConcept C2778749236 @default.
• W3016097788 hasConcept C2780699112 @default.
• W3016097788 hasConcept C2781100027 @default.
• W3016097788 hasConcept C2781413609 @default.
• W3016097788 hasConcept C71924100 @default.
• W3016097788 hasConcept C72563966 @default.
• W3016097788 hasConceptScore W3016097788C118487528 @default.
• W3016097788 hasConceptScore W3016097788C126322002 @default.
• W3016097788 hasConceptScore W3016097788C141071460 @default.
• W3016097788 hasConceptScore W3016097788C167135981 @default.
• W3016097788 hasConceptScore W3016097788C197934379 @default.
• W3016097788 hasConceptScore W3016097788C201903717 @default.
• W3016097788 hasConceptScore W3016097788C23131810 @default.
• W3016097788 hasConceptScore W3016097788C2776403814 @default.
• W3016097788 hasConceptScore W3016097788C2776694085 @default.
• W3016097788 hasConceptScore W3016097788C2777288759 @default.
• W3016097788 hasConceptScore W3016097788C2777802072 @default.
• W3016097788 hasConceptScore W3016097788C2778257484 @default.
• W3016097788 hasConceptScore W3016097788C2778749236 @default.
• W3016097788 hasConceptScore W3016097788C2780699112 @default.
• W3016097788 hasConceptScore W3016097788C2781100027 @default.
• W3016097788 hasConceptScore W3016097788C2781413609 @default.
• W3016097788 hasConceptScore W3016097788C71924100 @default.
• W3016097788 hasConceptScore W3016097788C72563966 @default.
• W3016097788 hasIssue "1" @default.
• W3016097788 hasLocation W30160977881 @default.

• next